Examination of reduction of hepatic fat mass and hepatic fibrosis inhibitory effect of pemafibrate in type 2 diabetic patients with hyperlipidemia and non-alcoholic fatty liver
Not Applicable
Recruiting
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000044389
- Lead Sponsor
- Department of Endocrinology and Metabolism, Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 60
Inclusion Criteria
Not provided
Exclusion Criteria
1)Type 1 diabetes 2)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3)A pregnant woman and/or a woman under breast-feeding 4)Impaired kidney function (serum creatinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) 5)Diabetic proliferative retinopathy 6)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7)No treatment with other fibrate 8)Patient with intolerance of medical reasons by doctor.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Evaluation of changes in liver steatosis by controlled attenuation parameter(CAP) and liver fibrosis measurement (LSM) in Fibro scan
- Secondary Outcome Measures
Name Time Method